(PharmaNewsWire.Com, July 09, 2017 ) Acute myelocytic leukemia (AML) , also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 18, 98, 105, 1, 5, 171, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 16, 14, 31 and 13 molecules, respectively.
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) . - The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles 4SC AG A. Menarini Industrie Farmaceutiche Riunite Srl AB Science SA AbbVie Inc Actinium Pharmaceuticals Inc ADC Therapeutics Sarl Advenchen Laboratories LLC Aeglea BioTherapeutics Inc Affichem SA Agios Pharmaceuticals Inc Aileron Therapeutics Inc AIMM Therapeutics BV Alexion Pharmaceuticals Inc Altor BioScience Corp Amgen Inc Antigen Express Inc Antisense Therapeutics Ltd APIM Therapeutics AS Aptevo Therapeutics Inc Aptose Biosciences Inc arGEN-X BV Ariad Pharmaceuticals Inc Arno Therapeutics Inc Arog Pharmaceuticals Inc Array BioPharma Inc Aslan Pharmaceuticals Pte Ltd Astellas Pharma Inc Asterias Biotherapeutics Inc Astex Pharmaceuticals Inc AstraZeneca Plc Atara Biotherapeutics Inc Athenex Inc Aurigene Discovery Technologies Ltd AVEO Pharmaceuticals Inc Bayer AG BCI Pharma Bellicum Pharmaceuticals Inc BerGenBio ASA Bio-Cancer Treatment International Ltd Bio-Path Holdings Inc BioLineRx Ltd BioSight Ltd Blueprint Medicines Corp Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Calithera Biosciences Inc Cancer Therapeutics CRC Pty Ltd Cantargia AB Cantex Pharmaceuticals Inc Cascadian Therapeutics Inc Celgene Corp Cell Medica Ltd Celldex Therapeutics Inc Cellectar Biosciences Inc Cellectis SA Cellerant Therapeutics Inc Cellular Biomedicine Group Inc Celyad SA CharlestonPharma LLC Cielo Therapeutics Inc ConverGene LLC Critical Outcome Technologies Inc CSPC Pharmaceutical Group Limited CTI BioPharma Corp Cyclacel Pharmaceuticals Inc Daiichi Sankyo Company Ltd DC Prime BV Deciphera Pharmaceuticals LLC eFFECTOR Therapeutics Inc Eisai Co Ltd Eli Lilly and Company Emercell SAS EntreChem SL EpiZyme Inc Erytech Pharma SA Esperance Pharmaceuticals Inc Exelixis Inc F. Hoffmann-La Roche Ltd Fate Therapeutics Inc FLX Bio Inc Forma Therapeutics Inc Formula Pharmaceuticals Inc Fortress Biotech Inc Forty Seven Inc Fujifilm Corp Gamida Cell Ltd Genentech Inc Genoscience Pharma Genosco Inc Gilead Sciences Inc GlaxoSmithKline Plc GlycoMimetics Inc Glycostem Therapeutics BV Golden Biotechnology Corp H3 Biomedicine Inc Hanmi Pharmaceuticals Co Ltd Hybrigenics SA Igenica Biotherapeutics Inc IGF Oncology LLC Ignyta Inc Immune Pharmaceuticals Inc Immune System Key Ltd ImmunGene Inc ImmunoGen Inc Immunomedics Inc Incyte Corp Inflection Biosciences Ltd Innovation Pharmaceuticals Inc Interprotein Corp Io Therapeutics Inc Jasco Pharmaceuticals LLC Jazz Pharmaceuticals Plc Jeil Pharmaceutical Co Ltd Johnson & Johnson JW Pharmaceutical Corp Kainos Medicine Inc
List of Tables Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..7) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..8) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..9) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..10) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..11) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..12) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..13) , H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3) , H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 Products under Development by Companies, H1 2017 (Contd..7) , H1 2017 Products under Development by Companies, H1 2017 (Contd..8) , H1 2017 Products under Development by Companies, H1 2017 (Contd..9) , H1 2017 Products under Development by Companies, H1 2017 (Contd..10) , H1 2017 Products under Development by Companies, H1 2017 (Contd..11) , H1 2017 Products under Development by Companies, H1 2017 (Contd..12) , H1 2017 Products under Development by Companies, H1 2017 (Contd..13) , H1 2017 Products under Development by Companies, H1 2017 (Contd..14) , H1 2017 Products under Development by Companies, H1 2017 (Contd..15) , H1 2017 Products under Development by Companies, H1 2017 (Contd..16) , H1 2017 Products under Development by Companies, H1 2017 (Contd..17) , H1 2017 Products under Development by Companies, H1 2017 (Contd..18) , H1 2017 Products under Development by Companies, H1 2017 (Contd..19) , H1 2017 Products under Development by Companies, H1 2017 (Contd..20) , H1 2017 Products under Development by Companies, H1 2017 (Contd..21) , H1 2017 Products under Development by Companies, H1 2017 (Contd..22) , H1 2017 Products under Development by Companies, H1 2017 (Contd..23) , H1 2017 Products under Development by Companies, H1 2017 (Contd..24) , H1 2017 Products under Development by Companies, H1 2017 (Contd..25) , H1 2017 Products under Development by Companies, H1 2017 (Contd..26) , H1 2017 Products under Development by Companies, H1 2017 (Contd..27) , H1 2017 Products under Development by Companies, H1 2017 (Contd..28) , H1 2017 Products under Development by Companies, H1 2017 (Contd..29) , H1 2017 Products under Development by Universities/Institutes, H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..3) , H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..4) , H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..5) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..6) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..7) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..8) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..9) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..10) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..11) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10) , H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ADC Therapeutics Sarl, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics BV, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Alexion Pharmaceuticals Inc, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Altor BioScience Corp, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antigen Express Inc, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antisense Therapeutics Ltd, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptevo Therapeutics Inc, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptose Biosciences Inc, H1 2017 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by arGEN-X BV, H1 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
